Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3′R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-
hexanoic acid 1-azabicyclo[2.2.2]oct-3′-yl ester di-
hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a
gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the
gastrointestinal disorder is gastroesophageal
reflux disease (
GERD), dyspepsia (such as functional dyspepsia or functional
motility disorder),
gastroparesis, paralytic
ileus, post-operative
ileus, emesis,
nausea,
heartburn, intestinal pseudo-obstruction,
irritable bowel syndrome (IBS),
constipation, enteral feeding intolerance (EFI), or
esophagitis. In some embodiments, the
gastrointestinal disorder is post-operative
ileus, chronic grass sickness,
constipation, megacolon,
gastritis, gastrointestinal stasis, or abomasal emptying defect.